Biochemistry

   

The Potential of the Biofield Energy Treated Novel Proprietary Test Formulation on Organs Specific Biomarkers

Authors: Inthirani Arul, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana

The study was investigated to find out the impact of the Biofield Energy Treated test formulation on the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Inthirani Arul, Canada and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The Biofield Energy Treated medium (BT-Med) + untreated test item (UT-TI) group showed 97.9% and 88.9% restoration of cell viability at 10 and 25 µg/mL, respectively as compared to the UT-Med + UT-TI group in human cardiac fibroblasts cells (HCF). Moreover, BT-Med + BT-TI group showed 62.8% and 86.2% restoration of cell viability at 1 and 63 µg/mL, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 125.6% (at 0.1 µg/mL) and 94.8% (at 63 µg/mL) restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI and BT-Med + UT-TI groups, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 81.8%, 83.9%, and 83.2% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 1430% (at 0.1 µg/mL), 332.6% (at 1 µg/mL), and 265% (at 0.1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 69% (at 1 µg/mL), 100.9% (at 0.1 µg/mL), and 76.9% (at 25 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 44.4% (at 0.1 µg/mL), 63.9% (at 10 µg/mL), and 84.9% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 35.1% and 78.3% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL compared to untreated in A549 cells. Serotonin level was significantly increased by 71.6%, 82.8%, and 104.8% in the BT-Med + BT-TI group at 1, 10, and 25 µg/mL, respectively as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 253.5% (at 1 µg/mL) and 270.3% (at 50 µg/mL) in the BT-Med + BT-TI group; while 235.2% at 10 µg/mL in the BT-Med + UT-TI group as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the relevant bones, heart, liver, lungs, and brain-related biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, liver cancer, Wilson disease, hemochromatosis, pneumonia, asthma, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.

Comments: 15 Pages.

Download: PDF

Submission history

[v1] 2019-09-03 04:22:32

Unique-IP document downloads: 3 times

Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.

Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.

comments powered by Disqus